SGMO - Sangamo Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.40
+0.34 (+2.60%)
At close: 4:00PM EDT

13.78 +0.38 (2.84%)
After hours: 6:18PM EDT

Stock chart is not supported by your current browser
Previous Close13.06
Open12.79
Bid13.50 x 900
Ask13.80 x 2200
Day's Range12.68 - 13.83
52 Week Range11.30 - 27.50
Volume1,573,348
Avg. Volume2,271,540
Market Cap1.362B
Beta (3Y Monthly)3.25
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.43
Trade prices are not sourced from all markets
  • Is Sangamo Therapeutics Inc. a Buy?
    Motley Fool5 days ago

    Is Sangamo Therapeutics Inc. a Buy?

    Can this beaten-down gene-editing and gene therapy biotech bounce back?

  • GlobeNewswire6 days ago

    Analysis: Positioning to Benefit within New York, KB Home, Sangamo Therapeutics, INTL FCStone, Maiden, and MobileIron — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Taking Stock of Gilead’s Operational Performance
    Market Realist15 days ago

    Taking Stock of Gilead’s Operational Performance

    Gilead Sciences’ (GILD) selling, general, and administrative expenses increased from $897.0 million in the second quarter of 2017 to $980.0 million in the second quarter. The increase was due to higher stock-based compensation expenses and costs after the Kite acquisition.

  • Sangamo Therapeutics Stock Is in Bearish Territory
    Market Realist18 days ago

    Sangamo Therapeutics Stock Is in Bearish Territory

    On October 4, Sangamo Therapeutics (SGMO) stock ended the trading day at $14.81—down ~3.4% from the previous day’s close. The stock registered its 52-week high of $27.50 on February 22. Sangamo Therapeutics reported its 52-week low of $11.30 on October 26, 2017. Currently, the stock is trading ~5.5% lower than its 50-day moving average of $15.68 and ~9% lower than its 200-day moving average of $16.27.

  • Sangamo Therapeutics: Analysts Expect 88% Upside Potential
    Market Realist18 days ago

    Sangamo Therapeutics: Analysts Expect 88% Upside Potential

    Sangamo Therapeutics (SGMO), a clinical stage biotechnology firm, is focused on developing gene-based therapies using industry-leading technology platforms in gene therapy, cell therapy, genome editing, and gene regulation. The company has collaborations with a number of leading pharmaceuticals firms including Gilead Sciences (GILD), Sanofi (SNY), and Pfizer (PFE) to develop a wide range of genomic therapies. In this part, we’ll discuss Sangamo Therapeutics’ recent recommendations and target prices from Wall Street analysts.

  • PR Newswire22 days ago

    Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares

    RICHMOND, Calif. and VALBONNE, France, Oct. 1, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) and TxCell S.A. (TXCL.PA) today jointly announced the completion by Sangamo of the acquisition of ordinary shares of TxCell, at a price of €2.58 per share in cash, representing approximately 53% of the share capital and voting rights of TxCell, as per the terms of the Share Purchase Agreement entered into on July 20, 2018 (the "SPA") and announced previously by TxCell and Sangamo in a joint press release dated July 23, 2018.

  • Implied Volatility Surging for Sangamo Therapeutics (SGMO) Stock Options
    Zacks28 days ago

    Implied Volatility Surging for Sangamo Therapeutics (SGMO) Stock Options

    Investors need to pay close attention to Sangamo Therapeutics (SGMO) stock based on the movements in the options market lately.

  • PR Newswire29 days ago

    Sangamo Therapeutics Announces Participation At Upcoming Investor and Industry Conferences

    RICHMOND, Calif. , Sept. 24, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will participate in the following healthcare investor and industry conferences ...

  • ACCESSWIRElast month

    Major Stem Cell Breakthroughs Giving Investors Big Opportunity

    HENDERSON, NV / ACCESSWIRE / September 14, 2018 / Last week, Sangamo Therapeutics became the first company to edit a patient's DNA inside the body, usually the process is done outside the body. This is ...

  • Why Analysts Remain Bullish on Sangamo Therapeutics
    Market Realistlast month

    Why Analysts Remain Bullish on Sangamo Therapeutics

    Its net loss per share was $0.17 in the second quarter of 2017. Six of them have given Sangamo stock a “buy” or higher rating, and one has rated it a “hold.” The mean rating for Sangamo stock is 1.71 with a target price of $27.83, implying an upside potential of 89.32% over its closing price of $14.70 on September 11. In comparison, peers Biogen (BIIB), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD) have mean ratings of 2, 1.78, and 2.15, respectively, and target prices of $389.20, $119.35, and $87.87, respectively.

  • Sangamo Therapeutics: The Promise of Zinc Fingers
    Market Realistlast month

    Sangamo Therapeutics: The Promise of Zinc Fingers

    Sangamo Therapeutics (SGMO) is focused on developing and commercializing novel genomic therapies. Its genome editing and gene regulation platform is based on the engineering of a type of transcription factors called zinc finger DNA binding proteins (or ZFP) that naturally occur in humans. Sangamo has entered into key collaborations with Kite Pharma, a subsidiary of Gilead Sciences (GILD) and Pfizer (PFE).

  • Audentes Therapeutics’ Promising Product Pipeline
    Market Realistlast month

    Audentes Therapeutics’ Promising Product Pipeline

    Gene therapy involves repairing or replacing disease-causing genes. Investor interest in gene therapy stocks has remained buoyant throughout 2018. According to Allied Market Research, the gene therapy market is expected to grow at a 33.3% CAGR (compound annual growth rate) to $4.4 billion by 2023.

  • Who Are The Major Shareholders Of Sangamo Therapeutics Inc (NASDAQ:SGMO)?
    Simply Wall St.last month

    Who Are The Major Shareholders Of Sangamo Therapeutics Inc (NASDAQ:SGMO)?

    A look at the shareholders of Sangamo Therapeutics Inc (NASDAQ:SGMO) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while hugeRead More...

  • A Financial Overview of Intellia Therapeutics in September
    Market Realistlast month

    A Financial Overview of Intellia Therapeutics in September

    In the second quarter, Intellia Therapeutics (NTLA) reported collaboration revenue of $7.7 million compared to $5.9 million in the second quarter of 2017. Intellia Therapeutics’ collaboration agreement with Regeneron Pharmaceuticals (REGN) primarily contributed to the increase in its collaboration revenue in the second quarter. In the first half of 2018, Intellia Therapeutics reported net collaboration revenue of $15.1 million compared to $12.1 million in the first half of 2017.

  • How CRISPR Therapeutics Is Positioned in September
    Market Realistlast month

    How CRISPR Therapeutics Is Positioned in September

    In the second quarter, CRISPR Therapeutics reported net income and EPS (earnings per share) of -$38.4 million and -$0.82, respectively, compared to net income and EPS of -$22.3 million and -$0.56 in the second quarter of 2017. In the first half of the year, CRISPR Therapeutics reported net income and EPS of -$66.7 million and -$1.44, respectively, compared to -$43.8 million and -$1.10 in the first half of 2017.

  • How Analysts View CRISPR Therapeutics in September
    Market Realistlast month

    How Analysts View CRISPR Therapeutics in September

    CRISPR Therapeutics (CRSP) has already obtained approval for clinical trial applications (or CTA) across multiple countries for its CTX001, an investigational autologous gene-edited hematopoietic stem cell therapy for the treatment of individuals with severe hemoglobinopathies. CRISPR Therapeutics and its partner, Vertex Pharmaceuticals, obtained CTA approvals for the evaluation of the therapy for the treatment of beta-thalassemia and sickle cell disease.

  • Sangamo Therapeutics stock drops 24% on results of cutting-edge gene-editing trial
    MarketWatchlast month

    Sangamo Therapeutics stock drops 24% on results of cutting-edge gene-editing trial

    The trial marked the first instance of gene editing, or adding a new copy of a gene into the DNA of a patient’s cells, completed inside the body.

  • Here’s What Was Behind Sangamo’s Horrendous Week
    Motley Foollast month

    Here’s What Was Behind Sangamo’s Horrendous Week

    The company reported disappointing data from a gene-editing trial.

  • Why Sangamo Therapeutics, Inc. Sank Again Today
    Motley Fool2 months ago

    Why Sangamo Therapeutics, Inc. Sank Again Today

    Disappointing interim results for its gene-editing therapy continued to weigh on the biotech stock.

  • Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint
    Zacks2 months ago

    Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint

    Gilead's (GILD) ankylosing spondylitis candidate, filgotinib meets primary endpoint in phase II study.

  • Bluebird Bio’s Valuation on September 6
    Market Realist2 months ago

    Bluebird Bio’s Valuation on September 6

    Bluebird Bio (BLUE) is a clinical stage biotechnology company. It reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline YoY (year-over-year) compared to $16.72 million in the second quarter of 2017.

  • Is This Gene-Editing Stock Doomed?
    Motley Fool2 months ago

    Is This Gene-Editing Stock Doomed?

    Investors had high expectations of the first clinical trial to edit the DNA of living humans, but they came away with concerns.

  • Zacks2 months ago

    Tough Day for Tech as NASDAQ Slips 1%+

    Tough Day for Tech as NASDAQ Slips 1%+

  • Sangamo's Zinc Fingers Fail Again. Time to Walk Away?
    Motley Fool2 months ago

    Sangamo's Zinc Fingers Fail Again. Time to Walk Away?

    Here's what investors need to know about the disappointing results Sangamo announced recently.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: ProQR Therapeutics and Sangamo Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Shares of one stock soared over 120% on positive results from a trial while the other collapsed on its trial results. ProQR was the winner with a gain of over 120% while Sangamo Therapeutics sank nearly 24%. ProQR Therapeutics N.V. shares exploded on Wednesday and closed up 120.75% on high trading volume.